Realistically you are looking at five years before any approval. The chance of success is <8% (on average).
The median phase III trial in their data set cost $21.4 million, they reported last year in Nature Reviews Drug Discovery. The median phase II trial cost $8.6 million, and the median phase I trial cost $3.4 million, they also reported.
https://www.nature.com/articles/nrd.2018.198
From the FDAStep 3: Clinical Research
Phase 2
Study Participants:Up to several hundred people with the disease/condition.
Length of Study: Several months to 2 years
Approximately 33% of drugs move to the next phase
Phase 3
Study Participants:300 to 3,000 volunteers who have the disease or condition
Length of Study: 1 to 4 years
Approximately 25-30% of drugs move to the next phase
https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
Ann: Media release - First stroke patient with afamelanotide, page-11
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |